travoprost 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
prostaglandins	2716	157283-68-6

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: izba travoprost travaprost travatan travatanz	A cloprostenol derivative that is used as an ANTIHYPERTENSIVE AGENT in the treatment of OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION. Molecular weight: 500.56 Formula: C26H35F3O6 CLOGP: 3.92 LIPINSKI: 1 HAC: 6 HDO: 3 TPSA: 96.22 ALOGS: -4.82 ROTB: 14 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

izba
travoprost
travaprost
travatan
travatanz

A cloprostenol derivative that is used as an ANTIHYPERTENSIVE AGENT in the treatment of OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.

Molecular weight: 500.56
Formula: C26H35F3O6
CLOGP: 3.92
LIPINSKI: 1
HAC: 6
HDO: 3
TPSA: 96.22
ALOGS: -4.82
ROTB: 14

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
Nov. 27, 2001	EMA
March 16, 2001	FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Treatment failure	499.66	18.68	294	6621	198749	63283358
Intraocular pressure increased	324.01	18.68	84	6831	5994	63476113
Eye irritation	272.61	18.68	99	6816	21872	63460235
Ocular hyperaemia	270.44	18.68	102	6813	25042	63457065
Malignant mediastinal neoplasm	204.13	18.68	44	6871	1402	63480705
Glaucoma	172.19	18.68	68	6847	18837	63463270
Blood immunoglobulin E increased	161.31	18.68	44	6871	3805	63478302
Eye pain	143.02	18.68	71	6844	33783	63448324
Product delivery mechanism issue	116.61	18.68	22	6893	350	63481757
Product packaging quantity issue	103.43	18.68	25	6890	1334	63480773
Bronchiectasis	99.57	18.68	44	6871	16098	63466009
Full blood count abnormal	92.63	18.68	52	6863	31665	63450442
Eye pruritus	75.38	18.68	38	6877	18633	63463474
Product container issue	63.64	18.68	18	6897	1775	63480332
Foreign body sensation in eyes	59.73	18.68	18	6897	2216	63479891
Dry eye	56.92	18.68	42	6873	40719	63441388
Nasal congestion	56.48	18.68	51	6864	65609	63416498
Rhinorrhoea	54.57	18.68	50	6865	65527	63416580
Visual acuity reduced	53.64	18.68	32	6883	21794	63460313
Intraocular pressure decreased	49.54	18.68	9	6906	115	63481992
Eye allergy	49.30	18.68	13	6902	986	63481121
Vision blurred	48.85	18.68	55	6860	91869	63390238
Product quality issue	47.93	18.68	36	6879	35829	63446278
Asthma	44.80	18.68	62	6853	127499	63354608
Product container seal issue	40.86	18.68	8	6907	156	63481951
Wheezing	38.98	18.68	50	6865	95545	63386562
Growth of eyelashes	38.44	18.68	8	6907	214	63481893
Retinal disorder	38.32	18.68	12	6903	1678	63480429
Visual impairment	37.34	18.68	46	6869	84400	63397707
Normal tension glaucoma	37.08	18.68	6	6909	36	63482071
Eye disorder	35.37	18.68	25	6890	22660	63459447
Intraocular pressure test abnormal	34.53	18.68	7	6908	164	63481943
Cough	34.48	18.68	89	6826	292654	63189453
Liquid product physical issue	33.66	18.68	10	6905	1172	63480935
Lacrimation increased	32.77	18.68	23	6892	20608	63461499
Reaction to preservatives	32.71	18.68	7	6908	215	63481892
Expired product administered	32.24	18.68	15	6900	6166	63475941
Blindness	31.73	18.68	23	6892	21676	63460431
Accidental exposure to product	31.15	18.68	25	6890	27380	63454727
Eye inflammation	30.49	18.68	14	6901	5585	63476522
Eye swelling	29.73	18.68	23	6892	23895	63458212
Corneal disorder	29.45	18.68	10	6905	1804	63480303
Subacute cutaneous lupus erythematosus	29.37	18.68	11	6904	2632	63479475
Ocular discomfort	27.58	18.68	12	6903	4221	63477886
Hypoacusis	27.38	18.68	22	6893	24129	63457978
Conjunctival hyperaemia	26.80	18.68	10	6905	2369	63479738
Eyelid irritation	26.48	18.68	7	6908	536	63481571
Dark circles under eyes	26.06	18.68	7	6908	570	63481537
Optic nerve injury	26.05	18.68	7	6908	571	63481536
Corneal irritation	24.38	18.68	3	6912	0	63482107
Corneal opacity	24.31	18.68	7	6908	736	63481371
Gastrointestinal bacterial infection	23.34	18.68	7	6908	847	63481260
Blepharitis	22.01	18.68	9	6906	2716	63479391
Photophobia	22.01	18.68	17	6898	17618	63464489
Blepharal pigmentation	20.95	18.68	4	6911	68	63482039
Gastroenteritis salmonella	20.21	18.68	6	6909	701	63481406
Product use complaint	19.40	18.68	8	6907	2466	63479641
Macular oedema	18.96	18.68	9	6906	3868	63478239
Ulcerative keratitis	18.70	18.68	8	6907	2702	63479405

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Treatment failure	525.33	19.26	195	3625	46502	34906609
Eye irritation	198.40	19.26	60	3760	7501	34945610
Intraocular pressure increased	159.77	19.26	47	3773	5336	34947775
Ocular hyperaemia	158.51	19.26	56	3764	11396	34941715
Product delivery mechanism issue	99.18	19.26	17	3803	151	34952960
Eye pain	87.21	19.26	38	3782	13424	34939687
Growth of eyelashes	64.76	19.26	11	3809	92	34953019
Eye pruritus	48.02	19.26	21	3799	7468	34945643
Expired product administered	41.13	19.26	15	3805	3326	34949785
Eye inflammation	35.09	19.26	12	3808	2206	34950905
Glaucoma	33.64	19.26	16	3804	6896	34946215
Visual acuity reduced	32.82	19.26	21	3799	16128	34936983
Visual impairment	31.09	19.26	28	3792	35774	34917337
Foreign body sensation in eyes	30.07	19.26	8	3812	626	34952485
Conjunctival scar	29.89	19.26	6	3814	133	34952978
Blindness	29.25	19.26	19	3801	14967	34938144
Product container issue	29.07	19.26	8	3812	711	34952400
Blepharitis	27.56	19.26	9	3811	1436	34951675
Vision blurred	25.20	19.26	28	3792	45935	34907176
Adrenal cyst	23.21	19.26	5	3815	158	34952953
Vitreous floaters	22.80	19.26	10	3810	3575	34949536
Product packaging quantity issue	22.74	19.26	7	3813	922	34952189
Electrolyte depletion	22.21	19.26	5	3815	194	34952917
Retinal detachment	21.80	19.26	11	3809	5380	34947731
Hepatitis fulminant	21.31	19.26	10	3810	4180	34948931
Eyelid margin crusting	20.90	19.26	5	3815	254	34952857
Intraocular pressure test abnormal	20.62	19.26	4	3816	74	34953037
Blindness unilateral	20.54	19.26	10	3810	4532	34948579
Product quality issue	20.31	19.26	16	3804	17019	34936092
Corneal oedema	20.17	19.26	7	3813	1344	34951767
Lacrimation increased	19.67	19.26	12	3808	8470	34944641

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Malignant mediastinal neoplasm	205.58	16.71	43	7480	1372	79735493
Intraocular pressure increased	186.78	16.71	58	7465	9147	79727718
Ocular hyperaemia	155.32	16.71	68	7455	28138	79708727
Eye irritation	154.64	16.71	62	7461	20619	79716246
Blood immunoglobulin E increased	144.73	16.71	43	7480	5839	79731026
Bronchiectasis	88.81	16.71	43	7480	22343	79714522
Full blood count abnormal	85.16	16.71	51	7472	40423	79696442
Eye pain	75.57	16.71	46	7477	37532	79699333
Rhinorrhoea	66.39	16.71	56	7467	76018	79660847
Visual acuity reduced	59.05	16.71	36	7487	29433	79707432
Nasal congestion	56.04	16.71	51	7472	76501	79660364
Glaucoma	55.27	16.71	30	7493	19731	79717134
Blepharitis	48.22	16.71	16	7507	3108	79733757
Asthma	45.85	16.71	60	7463	135035	79601830
Conjunctival hyperaemia	39.20	16.71	15	7508	4398	79732467
Wheezing	38.32	16.71	51	7472	116613	79620252
Normal tension glaucoma	35.23	16.71	6	7517	60	79736805
Eye inflammation	33.78	16.71	15	7508	6398	79730467
Vision blurred	32.80	16.71	45	7478	105853	79631012
Corneal disorder	32.45	16.71	11	7512	2280	79734585
Erythema of eyelid	31.21	16.71	11	7512	2559	79734306
Corneal oedema	31.01	16.71	11	7512	2609	79734256
Eye pruritus	30.98	16.71	21	7502	20549	79716316
Retinal disorder	29.67	16.71	10	7513	2037	79734828
Hepatitis fulminant	28.94	16.71	14	7509	7248	79729617
Growth of eyelashes	28.65	16.71	6	7517	192	79736673
Conjunctival scar	28.11	16.71	6	7517	211	79736654
Cough	28.00	16.71	87	7436	366702	79370163
Subacute cutaneous lupus erythematosus	27.72	16.71	11	7512	3550	79733315
Blindness	27.04	16.71	22	7501	28361	79708504
Vitreous floaters	25.97	16.71	13	7510	7243	79729622
Choroidal effusion	25.95	16.71	7	7516	670	79736195
Foreign body sensation in eyes	25.31	16.71	9	7514	2148	79734717
Keratic precipitates	25.03	16.71	6	7517	357	79736508
Corneal irritation	24.81	16.71	3	7520	0	79736865
Adrenal cyst	23.70	16.71	5	7518	166	79736699
Intraocular pressure decreased	23.39	16.71	5	7518	177	79736688
Corneal opacity	23.11	16.71	7	7516	1013	79735852
Lacrimation increased	22.64	16.71	18	7505	22459	79714406
Trabeculectomy	22.32	16.71	4	7519	55	79736810
Blindness transient	21.46	16.71	10	7513	4766	79732099
Eye disorder	19.92	16.71	17	7506	23395	79713470
Eye discharge	19.24	16.71	10	7513	6024	79730841
Electrolyte depletion	19.16	16.71	5	7518	421	79736444
Punctate keratitis	19.10	16.71	6	7517	980	79735885
Open angle glaucoma	18.92	16.71	5	7518	442	79736423
Cystoid macular oedema	18.56	16.71	7	7516	1973	79734892
Cornea verticillata	18.07	16.71	4	7519	167	79736698
Visual field defect	17.98	16.71	11	7512	9034	79727831
Stag horn calculus	17.96	16.71	4	7519	172	79736693
Ulcerative keratitis	17.43	16.71	8	7515	3681	79733184
Hypoglycaemia	17.42	16.71	33	7490	101561	79635304
Tracheo-oesophageal fistula	17.42	16.71	5	7518	601	79736264
Choroidal detachment	17.18	16.71	5	7518	631	79736234

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	S01EE04	SENSORY ORGANS OPHTHALMOLOGICALS ANTIGLAUCOMA PREPARATIONS AND MIOTICS Prostaglandin analogues
FDA CS	M0017805	Prostaglandins
FDA EPC	N0000175454	Prostaglandin Analog
MeSH PA	D000959	Antihypertensive Agents
MeSH PA	D002317	Cardiovascular Agents
CHEBI has role	CHEBI:35674	antihypertensive drugs
CHEBI has role	CHEBI:39456	antiglaucoma agent
CHEBI has role	CHEBI:50266	Prodrugs
CHEBI has role	CHEBI:66900	prostaglandin receptor agonists
CHEBI has role	CHEBI:66981	ophthalmology drugs

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Ocular hypertension	indication	4210003	DOID:9282
Open-angle glaucoma	indication	84494001	DOID:1067
Iritis	contraindication	65074000	DOID:1406
Uveitis	contraindication	128473001	DOID:13141
Cystoid macular edema	contraindication	193387007	DOID:4447

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Prostaglandin F2-alpha receptor	GPCR	P43088	PF2R_HUMAN	AGONIST	Ki	7.28		SCIENTIFIC LITERATURE	SCIENTIFIC LITERATURE
Prostaglandin E2 receptor EP3 subtype	GPCR	P43115	PE2R3_HUMAN		Ki	5.46		SCIENTIFIC LITERATURE

External reference:

ID	Source
4021261	VUID
N0000148702	NUI
D01964	KEGG_DRUG
4021261	VANDF
C0937916	UMLSCUI
CHEBI:746859	CHEBI
CHEMBL1200799	ChEMBL_ID
D000069557	MESH_DESCRIPTOR_UI
DB00287	DRUGBANK_ID
7102	IUPHAR_LIGAND_ID
7775	INN_ID
WJ68R08KX9	UNII
5282226	PUBCHEM_CID
1539201	RXNORM
15936	MMSL
200905	MMSL
41255	MMSL
88661	MMSL
d04753	MMSL
009114	NDDF
129493000	SNOMEDCT_US
391664000	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Travatan Z	HUMAN PRESCRIPTION DRUG LABEL	1	0078-0946	SOLUTION/ DROPS	0.04 mg	OPHTHALMIC	NDA	25 sections
Travatan Z	HUMAN PRESCRIPTION DRUG LABEL	1	0078-0946	SOLUTION/ DROPS	0.04 mg	OPHTHALMIC	NDA	25 sections
Travatan Z	HUMAN PRESCRIPTION DRUG LABEL	1	0078-0946	SOLUTION/ DROPS	0.04 mg	OPHTHALMIC	NDA	25 sections
Travoprost Ophthalmic Solution, 0.004%	HUMAN PRESCRIPTION DRUG LABEL	1	0378-9651	SOLUTION/ DROPS	0.04 mg	OPHTHALMIC	ANDA	22 sections
Travoprost Ophthalmic Solution, 0.004%	HUMAN PRESCRIPTION DRUG LABEL	1	0378-9651	SOLUTION/ DROPS	0.04 mg	OPHTHALMIC	ANDA	22 sections
Travoprost Ophthalmic Solution	HUMAN PRESCRIPTION DRUG LABEL	1	0781-6185	SOLUTION/ DROPS	0.04 mg	OPHTHALMIC	NDA authorized generic	22 sections
Travoprost Ophthalmic	HUMAN PRESCRIPTION DRUG LABEL	1	42571-130	SOLUTION	0.04 mg	OPHTHALMIC	ANDA	22 sections
Travoprost Ophthalmic	HUMAN PRESCRIPTION DRUG LABEL	1	42571-130	SOLUTION	0.04 mg	OPHTHALMIC	ANDA	22 sections
Travoprost	HUMAN PRESCRIPTION DRUG LABEL	1	51407-731	SOLUTION	0.04 mg	OPHTHALMIC	ANDA	22 sections
Travatan Z	HUMAN PRESCRIPTION DRUG LABEL	1	54868-5968	SOLUTION	0.04 mg	OPHTHALMIC	NDA	22 sections
Travoprost	HUMAN PRESCRIPTION DRUG LABEL	1	60505-0593	SOLUTION	0.04 mg	OPHTHALMIC	ANDA	22 sections
Travoprost	HUMAN PRESCRIPTION DRUG LABEL	1	60505-0593	SOLUTION	0.04 mg	OPHTHALMIC	ANDA	22 sections
Travoprost Ophthalmic Solution USP, 0.004%Travoprost	Human Prescription Drug Label	1	62332-510	SOLUTION/ DROPS	0.04 mg	OPHTHALMIC	ANDA	22 sections
Travoprost Ophthalmic Solution USP, 0.004%Travoprost	Human Prescription Drug Label	1	62332-510	SOLUTION/ DROPS	0.04 mg	OPHTHALMIC	ANDA	22 sections
Travoprost Ophthalmic Solution	HUMAN PRESCRIPTION DRUG LABEL	1	63629-8839	SOLUTION/ DROPS	0.04 mg	OPHTHALMIC	NDA authorized generic	22 sections
Travoprost Ophthalmic Solution	HUMAN PRESCRIPTION DRUG LABEL	1	63629-8839	SOLUTION/ DROPS	0.04 mg	OPHTHALMIC	NDA authorized generic	22 sections
Travoprost Ophthalmic Solution	HUMAN PRESCRIPTION DRUG LABEL	1	63629-8840	SOLUTION/ DROPS	0.04 mg	OPHTHALMIC	NDA authorized generic	22 sections
Travoprost Ophthalmic Solution	HUMAN PRESCRIPTION DRUG LABEL	1	63629-8840	SOLUTION/ DROPS	0.04 mg	OPHTHALMIC	NDA authorized generic	22 sections